Citigroup
INKT icon

Citigroup’s MiNK Therapeutics INKT Stock Holding History

Citigroup’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$958 Sell
91
-246
-73% -$2.74K ﹤0.01% 5486
2025
Q4 		$3.76K Buy
+337
New +$4.35K ﹤0.01% 5325
2022
Q3 		– Sell
-2
Closed – – 6067
2022
Q2 		$0 Sell
2
-6
-75% -$113 ﹤0.01% 6425
2022
Q1 		$0 Sell
8
-83
-91% -$2.49K ﹤0.01% 6463
2021
Q4 		$4K Buy
+91
New +$10.8K ﹤0.01% 5678

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup's INKT Position: Q1 2026 in Review

Citigroup reduced its MiNK Therapeutics (INKT) stake by 73% in Q1 2026, selling an estimated $2.74K and leaving 91 shares worth $958. The position accounts for ﹤0.01% of the portfolio, ranked #5486.

Citigroup first reported a position in INKT in Q4 2021 and has held it in 5 quarters since. The position peaked at $4K in Q4 2021. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Citigroup held 91 shares of MiNK Therapeutics worth $958 as of Q1 2026.
  • Citigroup sold 246 MiNK Therapeutics shares in Q1 2026, an estimated $2.74K.
  • MiNK Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5486 holding.
  • Citigroup first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Citigroup's MiNK Therapeutics position peaked at $4K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.